预约演示
更新于：2025-08-29
Ephedrine Hydrochloride
盐酸麻黄碱
更新于：2025-08-29
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2017-03-03), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C10H16ClNO |
InChIKeyBALXUFOVQVENIU-GNAZCLTHSA-N |
CAS号50-98-6 |
关联
44
项与 盐酸麻黄碱 相关的临床试验CTIS2024-517933-42-00
A blinded randomized study of ephedrine 0.15 mg/kg for reducing onset time of rocuronium 0.6 mg/kg in elderly patients (= 80 years)
ChiCTR2400088799
Study on the Effects of Ephedrine and Norepinephrine Treatment on Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery Following General Anesthesia-Induced Hypotension
IRCT20230516058204N1
Prophylactic administration of ephedrine and hydroxyethyl starch before spinal anesthesia to prevent hypotension in patients undergoing cesarean section
100 项与 盐酸麻黄碱 相关的临床结果
登录后查看更多信息
100 项与 盐酸麻黄碱 相关的转化医学
登录后查看更多信息
100 项与 盐酸麻黄碱 相关的专利（医药）
登录后查看更多信息
5,283
项与 盐酸麻黄碱 相关的文献（医药）2025-12-01Current Drug Delivery
Improvement in Compatibility and Drug Release Performance of Hot-Melt
Pressure-Sensitive Adhesives by Physical Blending Technique
Article
作者: Feng, Nianping ; Zhang, Yangyang ; Yin, Shuo ; Wu, Tan ; Guo, Teng ; Yang, Jiayi ; Zhu, Chunyun
Background::
Hot-melt Pressure-sensitive Adhesives (HMPSA) are eco-friendly pressuresensitive
adhesives, with the potential of being used as substrates for transdermal patches. However,
due to the low hydrophilicity of HMPSA, the application is limited in the field of Traditional Chinese
Medicine (TCM) plasters.
Methods::
Three modified HMPSA were prepared with acrylic resin EPO, acrylic resin RL100, and
Polyvinylpyrrolidone (PVP) as the modifying materials. The physical compatibility between HMPSA
and the modifying materials was investigated through in vitro release performance, viscosity, softening
point, cohesion, and fluidity, so as to determine the most effective modifying material. The impact
of the modified HMPSA on the release properties of different TCM ingredients was elucidated
by the performance of water absorption and contact angle behavior.
Results::
With the addition of the modifying materials, both the viscosity and the softening point of
HMPSA were improved, with the flowability reduced and the cohesion maintained. The morphological
and structural changes reflected the physical compatibility between HMPSA and the three modifying
materials. According to the results of in vitro release experiments, PVP effectively improved
the release performance of paeoniflorin, ephedrine hydrochloride, and cinnamaldehyde in HMPSA,
with no significant impact on the release performance of eugenol. The changes in the drug release
performance of HMPSA may be attributed to the improved hydrophilicity of HMPSA after physical
modification.
Conclusion::
The compatibility and the drug release performance of HMPSA were effectively enhanced
after the addition of the modifying materials by the physical blending technique. Among the
three modifying materials, PVP has been found to be an ideal modifying material for HMPSA in the
field of TCM plasters due to its effects on drug release performance.
2025-10-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Investigation of the material basis and mechanism of Qingfei Paidu granules in treating LPS-induced acute pneumonia using UPLC-Q-TOF-MS/MS, network pharmacology, molecular docking and experimental verification
Article
作者: Zhao, Hao ; Wang, Xing ; Guo, Qiang ; Ma, Ruonan ; Zhang, Yuxin ; Wu, Xia ; Li, Huizhen ; Ma, Yuqing
Qingfei Paidu granules (QFPDG), derived from four classic traditional Chinese medicine formulas with a centuries-long history of treating respiratory disorders, have shown remarkable clinical efficacy against pneumonia and lung injury, yet their pharmacodynamic components and mechanisms require further elucidation. In this work, UPLC-Q-TOF-MS/MS was used to identify the chemical constituents in QFPDG, drug-containing serum, and lung tissue. Network pharmacology was employed to predict key targets and pathways. The anti-pneumonia efficacy was evaluated via an LPS-induced acute pneumonia mouse model and by measuring cytokine levels in LPS-stimulated RAW264.7 cells. Finally, Molecular docking along with molecular dynamics simulation was conducted to explore the interactions between key compounds and targets. Results showed that 145 compounds were identified in QFPDG solution, 94 in serum, and 83 in lung tissue, with 97 components in serum and lung associated with 350 pneumonia-related targets and crucial pathways. QFPDG alleviated acute lung injury and inflammation in LPS-induced acute pneumonia mice, reducing monocyte, neutrophil, lymphocyte, and leukocyte counts in bronchoalveolar lavage fluid (BALF), as well as decreasing TNF-α and IL-1β levels. Molecular docking and molecular dynamics simulations showed that five key components in QFPDG had strong binding affinities for TNF-α, IL-1β, IL-6 and AKT1 with minimal fluctuations at equilibrium. Binding free energy calculations indicated that the ∆Gbind values ranging from -8.59 to -41.98 kcal/mol, primarily driven by hydrophobic and electrostatic interactions, involving key amino acid residues like Glu93, Tyr97, Tyr119, Gly121, and Tyr151. In summary, QFPDG presents a multi-component, multi-target approach to treating pneumonia, targeting key signaling pathways including PI3K-AKT, MAPK, and TNF. The compound-target interactions clarify its anti-inflammatory and tissue-protective mechanisms, suggesting potential for clinical application and pharmaceutical development.
2025-10-01TALANTA
Screening and validation of sponge materials assembled to a sampling device for enrichment and determination of amphetamine drugs in exhaled breath by HPLC-TQ-MS/MS
Article
作者: Yang, Xiangliang ; Xu, Fei ; Fan, Huajun ; Huang, Qingda ; Xu, Congfei ; Zhou, Jiedan ; Yang, Hai
Exhaled breath aerosol (EBA) analysis of the amphetamine drugs (AMPs) and ephedrine (EPH) has a great potential to monitor illicit drug abuse due to its simple, non-invasive, convenient, and easily accepted sampling. Nevertheless, the extremely low concentration of AMPs and EPH in EBA poses great challenges to instrumental analysis. In this study, a self-designed sampling device equipped with sponge-based material was developed and coupled to high-performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry (HPLC-TQ-MS/MS) for monitoring of the AMPs and EPH in EBA. Accordingly, the cellulose sponge with high adsorption performance and low expiratory resistance was screened out from multiple commercial sponges, optimized its configuration performance, and assembled to the sampling device, reaching the adsorption rates of 81.6 ± 2.2-98.9 ± 2.5 % for EPH and typical AMPs, including amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, and 3,4-methylenedioxymethamphetamine. The combination of HPLC-TQ-MS/MS and the device containing cellulose sponge showed excellent analytical performance, with linearity in the range of 30.0-20000.0 pg/filter (R ≥ 0.9901), low detection limit of 1.6-8.4 pg/filter, and the recoveries of 86.5-94.5 %. The device also exhibited good reusability and applicability for the simulated EBAs at different levels. Furthermore, the proposed method was successfully applied for determination of EPH in volunteers' EBAs, whose contents suggested a good correlation with that in saliva. Kinetic analysis provided insights into the adsorption mechanism, further validating reliability of the method. Overall, the simple, cheap, available, and reusable cellulose sponge assembled to sampling device was advantageous for enriching and monitoring of trace illicit drugs in human EBA.
100 项与 盐酸麻黄碱 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低血压 | 澳大利亚 | 2017-03-03 | |
| 哮喘 | - | - | - |
| 鼻塞 | - | - | - |
| 慢性阻塞性肺疾病 | - | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 28 | 糧網淵淵簾衊鏇築構壓(遞鏇鏇壓願選糧繭鹹繭) = 範選襯獵艱鏇膚鬱夢齋 簾餘構糧繭網觸憲鬱蓋 (積構遞鬱願網鏇蓋願醖 ) | - | 2020-04-01 | |||
临床2期 | 53 | Saline Placebo (Saline Placebo) | 簾獵淵範夢膚壓膚蓋齋(積齋蓋壓鏇願齋壓範襯) = 繭襯淵壓壓糧鏇餘鑰艱 襯襯獵範淵鹹築廠壓獵 (觸構網壓選襯鏇淵糧襯, 0.26) 更多 | - | 2017-05-22 | ||
(IM Ephedrine) | 簾獵淵範夢膚壓膚蓋齋(積齋蓋壓鏇願齋壓範襯) = 餘鑰鹽鏇鏇構範築淵鏇 襯襯獵範淵鹹築廠壓獵 (觸構網壓選襯鏇淵糧襯, 0) 更多 | ||||||
N/A | 90 | Caffeine/Ephedrine (CE) | 餘構廠醖遞繭壓遞淵鬱(鏇選鬱窪憲艱壓觸觸窪) = 鹽衊壓觸淵積積夢簾獵 觸觸願鬱簾鹽製製築淵 (積築糧觸範膚蓋範膚憲 ) 更多 | - | 2013-10-01 | ||
Leptin A-200 and Caffeine/Ephedrine (LCE) | 積廠簾網艱蓋淵鹹艱鹹(積構鬱齋築獵鏇齋蓋網) = 遞選艱齋網窪蓋艱獵鹹 餘繭齋糧夢簾顧鏇壓糧 (鹽窪鬱齋鏇窪襯構蓋製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用